IntelliPharmaCeutics International (IntelliPharmaCeutics International) Accounts Payable & Accrued Expense : $11.14 Mil (As of Aug. 2023)

View and export this data going back to 1996. Start your Free Trial

What is IntelliPharmaCeutics International Accounts Payable & Accrued Expense?

IntelliPharmaCeutics International's quarterly accounts payable & accrued expense increased from Feb. 2023 ($10.23 Mil) to May. 2023 ($10.48 Mil) and increased from May. 2023 ($10.48 Mil) to Aug. 2023 ($11.14 Mil).

IntelliPharmaCeutics International's annual accounts payable & accrued expense increased from Nov. 2020 ($7.59 Mil) to Nov. 2021 ($8.33 Mil) and increased from Nov. 2021 ($8.33 Mil) to Nov. 2022 ($9.68 Mil).

IntelliPharmaCeutics International Accounts Payable & Accrued Expense Historical Data

The historical data trend for IntelliPharmaCeutics International's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Accounts Payable & Accrued Expense Chart

IntelliPharmaCeutics International Annual Data

Trend

Nov13

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

3.22

5.58

7.59

8.33

9.68

IntelliPharmaCeutics International Quarterly Data
	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															9.58	9.68	10.23	10.48	11.14

IntelliPharmaCeutics International Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (OTCPK:IPCIF) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

I4AA:Germany IPCI:Canada

Address

30 Worcester Road, Toronto, ON, CAN, M9W 5X2

Website

https://www.intellipharmaceutics.com

IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.